XML 90 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Contracts (Details) (Daiichi Sankyo, USD $)
In Millions, unless otherwise specified
 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Apr. 30, 2011
Dec. 31, 2013
Jul. 31, 2011
Minimum
Country
Dec. 31, 2013
Minimum
Dec. 31, 2013
Maximum
Loss Contingencies [Line Items]          
Up-front fee and certain past reimbursements $ 1.6        
Future milestone payments payable   $ 10.0      
Period for which royalties will be paid following the first commercial sale of licensed products in the country   10 years      
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons   6 months      
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default   12 months      
Number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right waived after amendment to the agreement     1    
Percentage of increase in royalty due on future net sales of sapacitabine after amendment       1.25% 1.50%